Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep letter to ineligible shareholders (ASX:IMM)

On Monday, 3 June 2024, Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep or Company) announced a fully underwritten placement to institutional investors of new fully paid ordinary shares in Immut...read more

Immutep retail entitlement offer booklet (ASX:IMM)

Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep) is pleased to announce that it has today despatched a copy of the retail offer booklet (and accompanying personalised entitlement and acceptance ...read more

Immutep completes institutional pro-rata offer & placement (ASX:IMM)

Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep or the Company) is pleased to announce the successful completion of its institutional placement (Placement) and the institutional component (Insti...read more

Immutep announces Ph 3 clinical trial collaboration with MSD (ASX:IMM)

-- Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC) -- TACTI-004...read more

Immutep Capital Raising Presentation (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep - A$100 million fully underwritten equity raising (ASX:IMM)

Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep or Company) is pleased to announce that it has launched a fully underwritten approximately $100 million equity raising (Offer) through a pro rata ...read more

INOVIQ - Breakthrough Exosome Therapy (ASX:IIQ)

INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that it has successfully produced and isolated engineered exosomes (EEVs) that target and kill breast cancer cells in vitro. In a proof-o...read more

IVE Group announces Board changes (ASX:IGL)

Following the recent passing of IVE Group Limited’s Executive Chairman, Geoff Selig, the Company advises that non-executive director, James Todd, has been appointed as Chair of the IVE Board. ...read more

Immutep - AIPAC-003 safety lead-in data presented at ESMO Breast 2024 (ASX:IMM)

Confirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy achieved during combination treatment with 90mg efti and paclitaxel ...read more

Immutep - Positive initial data in phase 2 Soft Tissue Sarcoma trial (ASX:IMM)

Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trial Four ...read more

INOVIQ - Quarterly Activities Report and Appendix 4C - March 2024 (ASX:IIQ)

In lodging the quarterly business update, new Chairman David Williams said “IIQ has a unique offering that is partly de-risked by having its technology launched in the market. Better still, st...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg dosing of efti safe and well tolerated: 50% overall response rate, including one patie...read more

Immutep - Positive preliminary topline results from TACTI-003 Cohort B (ASX:IMM)

Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows a preliminary 26.9%...read more

INOVIQ - Ovarian Cancer Test Validation (ASX:IIQ)

INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce the successful completion of an analytical validation study for its blood test for ovarian cancer. Overall, the test correctly identified 85...read more

Immutep - CHDR to conduct first-in-human phase 1 trial of IMP761 (ASX:IMM)

-- Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address the under...read more

Viewing: 46 - 60 of 200 Previous | Next